European Medical Solutions (ALEMS.BR)
EUR 5.5
(0.0%)
EUR 5.5
(0.0%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -0.00 EUR | 86.49% |
| 2022 | -0.00 EUR | 63.0% |
| 2021 | -0.01 EUR | 83.92% |
| 2020 | -0.06 EUR | 91.92% |
| 2019 | -0.77 EUR | 10.47% |
| 2018 | -0.86 EUR | 8.51% |
| 2017 | -0.94 EUR | 14.55% |
| 2016 | -1.10 EUR | -20.88% |
| 2015 | -0.91 EUR | -19.74% |
| 2014 | -0.76 EUR | -90.0% |
| 2013 | -0.40 EUR | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 Q2 | 0.00 EUR | 145.45% |
| 2023 FY | - EUR | 86.49% |
| 2023 Q4 | -0.00 EUR | -300.0% |
| 2022 Q4 | -0.00 EUR | 59.26% |
| 2022 FY | - EUR | 63.0% |
| 2022 Q2 | -0.00 EUR | -101.5% |
| 2021 FY | - EUR | 83.92% |
| 2021 Q4 | 0.18 EUR | 4013.04% |
| 2021 Q2 | -0.00 EUR | -130.0% |
| 2020 Q2 | -0.06 EUR | 83.78% |
| 2020 FY | - EUR | 91.92% |
| 2020 Q4 | -0.00 EUR | 96.67% |
| 2019 Q4 | -0.37 EUR | 7.5% |
| 2019 FY | - EUR | 10.47% |
| 2019 Q2 | -0.40 EUR | 21.57% |
| 2018 Q4 | -0.51 EUR | -50.0% |
| 2018 FY | - EUR | 8.51% |
| 2018 Q2 | -0.34 EUR | 17.07% |
| 2017 Q2 | -0.53 EUR | -39.47% |
| 2017 Q4 | -0.41 EUR | 22.64% |
| 2017 FY | - EUR | 14.55% |
| 2016 Q2 | -0.77 EUR | 0.0% |
| 2016 FY | - EUR | -20.88% |
| 2016 Q4 | -0.38 EUR | 50.65% |
| 2015 Q2 | - EUR | 0.0% |
| 2015 Q4 | - EUR | 0.0% |
| 2015 FY | - EUR | -19.74% |
| 2014 FY | - EUR | -90.0% |
| 2013 FY | - EUR | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Nicox S.A. | -0.42 EUR | 99.881% |
| FERMENTALG | -0.32 EUR | 99.844% |
| argenx SE | -4.67 EUR | 99.989% |
| BioSenic S.A. | -0.21 EUR | 99.762% |
| Celyad Oncology SA | -0.33 EUR | 99.848% |
| Hyloris Pharmaceuticals SA | -0.55 EUR | 99.909% |
| Onward Medical N.V. | -1.20 EUR | 99.958% |
| Oxurion NV | -0.01 EUR | 95.652% |
| PHAXIAM Therapeutics S.A. | -5.00 EUR | 99.99% |
| Financière de Tubize SA | 1.98 EUR | 100.025% |
| UCB SA | 1.81 EUR | 100.028% |